Following the sale, the insider now directly owns 197,583 shares of the company's stock, valued at approximately $18,090,699.48. Palo Alto Investors LLC increased its stake in shares of Clovis Oncology by 2.4% in the first quarter. On the stock's most recent trading day, the company's shares ended the regular session at $55.87, which is 43.82% lower than its 52-week high. About 1.62 million shares traded or 28.73% up from the average.
BidaskClub lowered shares of Clovis Oncology (NASDAQ:CLVS) from a sell rating to a strong sell rating in a research report report published on Friday morning. It has outperformed by 266.01% the S&P500.
Credit Suisse Ag increased its stake in Unitedhealth Group Inc (UNH) by 9082.87% based on its latest 2017Q3 regulatory filing with the SEC. Skylands Capital Llc acquired 42,648 shares as Asure Software Inc (ASUR)'s stock rose 14.39%. The hedge fund run by David Goel held 2.27M shares of the commercial physical & biological resarch company at the end of 2017Q3, valued at $265.03M, up from 1.80 million at the end of the previous reported quarter. Rmb Cap Management Ltd accumulated 0.04% or 19,140 shares. In the last three months, insiders have sold 18,000 shares of company stock worth $1,123,425. About 842,616 shares traded. Asure Software, Inc. (NASDAQ:ASUR) has risen 137.62% since January 19, 2017 and is uptrending. It has outperformed by 8.19% the S&P500.More news: New poster of 'dhadak ' out, release shifted to July 20
Since August 4, 2017, it had 0 insider buys, and 7 sales for $2.78 million activity. (NASDAQ:CLVS) was sold by BLAIR JAMES C on Friday, August 4.
Investors sentiment decreased to 1.44 in 2017 Q3. Its down 1.50, from 3.5 in 2017Q2. It dropped, as 48 investors sold CLVS shares while 49 reduced holdings. Td Asset Mgmt owns 24,485 shares or 0% of their United States portfolio. Finally, Barclays began coverage on Clovis Oncology in a research note on Monday, October 23rd.
Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Wednesday, November 1st. Axa holds 35,400 shares or 0.01% of its portfolio. Roth Capital maintained Asure Software, Inc. Clearbridge Invests Ltd Liability Com invested in 173,058 shares. Nationwide Fund Advisors holds 0.05% in Clovis Oncology, Inc. (NASDAQ:CLVS). Fred Alger Mngmt Incorporated accumulated 0.32% or 828,407 shares. Dekabank Deutsche Girozentrale accumulated 47,800 shares or 0.03% of the stock. They expect $-1.27 EPS, up 30.60% or $0.56 from last year's $-1.83 per share. Abner Herrman Brock Limited Liability invested in 21,351 shares. The firm owned 13,690 shares of the biopharmaceutical company's stock after buying an additional 2,885 shares during the period. California State Teachers Retirement Sys invested in 70,356 shares or 0.01% of the stock. Hayek Kallen Invest Mngmt owns 57,446 shares. Asure Software Inc now has $187.75 million valuation. It also reduced Vanguard Tax Managed Intl Fd (VEA) stake by 211,216 shares and now owns 659,392 shares. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Therefore 100% are positive. Altria Group Inc. had 55 analyst reports since July 31, 2015 according to SRatingsIntel. As per Tuesday, November 17, the company rating was maintained by Northland Capital. JPMorgan Chase & Co. reaffirmed a buy rating on shares of Clovis Oncology in a research note on Thursday, January 11th. Prudential Financial Inc. now owns 4,388 shares of the biopharmaceutical company's stock valued at $411,000 after acquiring an additional 590 shares during the last quarter. The firm has "Hold" rating given on Monday, July 31 by Oppenheimer. The firm has "Buy" rating given on Thursday, July 27 by Piper Jaffray. The stock has "Neutral" rating by JP Morgan on Wednesday, April 13. As per Monday, September 11, the company rating was maintained by Stifel Nicolaus. (NASDAQ:CLVS) earned "Overweight" rating by PiperJaffray on Thursday, January 26. Zacks Investment Research cut shares of Clovis Oncology from a "buy" rating to a "hold" rating in a research note on Thursday, July 13th.More news: Rajasthan to appeal against Padmaavat release
Since August 1, 2017, it had 0 buys, and 6 selling transactions for $22.86 million activity. Another trade for 5,001 shares valued at $255,051 was sold by Casey Diane S. Shares for $415,230 were sold by Trower Paul. The insider Barrington Martin J. sold $994,909. $88,715 worth of Incyte Corporation (NASDAQ:INCY) was sold by Flannelly Barry P. BAKER BROS.
Additionally, according to the most recent 13F filing from Clovis Oncology, Inc.
Investors sentiment decreased to 0.89 in Q3 2017. Its down 0.01, from 1.34 in 2017Q2. 118 funds opened positions while 420 raised stakes. BURKE RICHARD T sold $2.88 million worth of stock. Highbridge Capital Management Ltd reported 0.06% in Clovis Oncology, Inc. The Michigan-based Greenleaf Tru has invested 0% in Incyte Corporation (NASDAQ:INCY). Biondo Invest Advisors Ltd Company holds 0.91% or 52,230 shares. HCSG's profit would be $24.18M giving it 39.43 P/E if the $0.33 EPS is correct. Tekla Management Lc has invested 2.89% in Incyte Corporation (NASDAQ:INCY). (NASDAQ:HCSG). State Of Tennessee Treasury Department reported 63,643 shares stake. Texas-based Hilltop Hldgs has invested 0.97% in Altria Group, Inc. (NASDAQ:CLVS). Us Retail Bank De stated it has 413 shares or 0% of all its holdings. Legal And General Group Pcl holds 0% or 17,962 shares. Fisher Asset Lc holds 0% of its portfolio in Clovis Oncology, Inc. Nicholas Investment Ptnrs Ltd Partnership stated it has 24,917 shares or 0.14% of all its holdings. (NASDAQ:CLVS) on Monday, January 25 with "Neutral" rating. Therefore 75% are positive. Ardsley Advisory Partners has 1.23% invested in Clovis Oncology, Inc.More news: What Americans have to say about Trump's maiden year
In other news, Director Thorlef Spickschen sold 4,500 shares of the business's stock in a transaction dated Monday, January 8th. This public company's current market capitalization stands at $2.79 billion. The rating was initiated by Suntrust Robinson with "Buy" on Friday, August 5. The rating was maintained by UBS with "Buy" on Wednesday, August 5. Leerink Swann reaffirmed an "outperform" rating and set a $90.00 price target (down from $107.00) on shares of Clovis Oncology in a research note on Wednesday, November 15th. The stock has "Buy" rating by Citigroup on Wednesday, July 19.